Abstract
In France, mifepristone (Myfegine [RU 486]), an oral antiprogesterone, has been available in hospitals since 1990. It is administered to women requesting abortion during early pregnancy (amenorrhea <50 days) together with an intravenous injection or vaginal suppository of a prostaglandin analogue. 1 We describe the first case of toxic epidermal necrolysis (TEN) after administration of mifepristone and gemeprost, a prostaglandin analogue.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
